# 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

> **NCT05483023** · PHASE2 · WITHDRAWN · sponsor: **UNC Lineberger Comprehensive Cancer Center**

## Conditions studied

- Complex Atypical Hyperplasia
- Endometrial Cancer

## Interventions

- **DRUG:** 18F-fluorofuranylnorprogesterone PET / MRI

## Key facts

- **NCT ID:** NCT05483023
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-02-15
- **Primary completion:** 2026-06-28
- **Final completion:** 2027-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Drug cannot be produced and scanner down.
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05483023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05483023, "18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05483023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*